This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04261075
Recruitment Status : Completed
First Posted : February 7, 2020
Last Update Posted : August 15, 2022
Information provided by (Responsible Party):
MedImmune LLC

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : June 16, 2022
Actual Study Completion Date : June 16, 2022